Home › Trials › NCT06767462

Assessing eye health in breast cancer patients

A Multicentre Study Assessing Ophthalmic Safety in Patients With Breast Cancer

Observational AstraZeneca · NCT06767462

This study is testing how breast cancer treatments affect eye health in patients over a year to better understand any changes they might experience.

Quick facts

Study typeObservational
Enrollment160 (estimated)
Ages18 Years to 130 Years
SexAll
SponsorAstraZeneca Industry-sponsored
Locations75 sites (La Jolla, California and 74 other locations)
Trial IDNCT06767462 on ClinicalTrials.gov

What this trial studies

This multicenter observational study evaluates the ophthalmic safety of patients with breast cancer who are participating in a qualifying study. It includes two cohorts of at least 60 individuals each, with assessments conducted over approximately 12 months. The study aims to account for age-related changes and worsening of pre-existing conditions by performing parallel ophthalmic assessments at the same timepoints. The goal is to gather comprehensive data on eye health in this patient population.

Who should consider this trial

Good fit: Ideal candidates are patients with breast cancer who are enrolled in a qualifying study and meet the specific eligibility criteria.

Not a fit: Patients not receiving study-assigned treatment in the qualifying study or those with contraindications to required ophthalmic procedures may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of eye health risks in breast cancer patients, leading to better monitoring and management strategies.

How similar studies have performed: While this study focuses on a specific aspect of patient safety, similar observational studies have shown success in assessing health outcomes in cancer patients.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Signed informed consent in the qualifying study.
2. Signed informed consent in the ophthalmic study prior to any ophthalmic study specific assessments and procedures.
3. Completed the baseline ophthalmic examination for this study before the first dose in the qualifying study.
4. Meets all the eligibility criteria in the qualifying study

Exclusion Criteria:

1. Patients not randomized and not receiving study assigned treatment in a qualifying study.
2. Patients with contraindications to any ophthalmic procedure required by the study or sensitivity/allergy to pupil dilating agents.
3. Judgement by the investigator that the patient should not participate in the ophthalmic study if the patient is unlikely to comply with study procedures, restrictions, and requirements

Where this trial is running

La Jolla, California and 74 other locations

+25 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Ophthalmic Safety in Patients With Breast CancerOphthalmic Safety assessment
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.